Compare ARDX & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | PENN |
|---|---|---|
| Founded | 2007 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2014 | 1996 |
| Metric | ARDX | PENN |
|---|---|---|
| Price | $5.69 | $14.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 15 |
| Target Price | $15.14 | ★ $20.29 |
| AVG Volume (30 Days) | 3.7M | ★ 4.6M |
| Earning Date | 05-12-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,607,000.00 | ★ $6,362,900,000.00 |
| Revenue This Year | $38.22 | $6.02 |
| Revenue Next Year | $33.85 | $4.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.50 | $11.65 |
| 52 Week High | $8.40 | $20.61 |
| Indicator | ARDX | PENN |
|---|---|---|
| Relative Strength Index (RSI) | 34.97 | 56.00 |
| Support Level | $5.49 | $13.87 |
| Resistance Level | $6.23 | $15.36 |
| Average True Range (ATR) | 0.31 | 0.86 |
| MACD | -0.06 | 0.10 |
| Stochastic Oscillator | 11.79 | 76.01 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.